13908-42-4

Basic information

• Product Name: 1-(2-chloroethyl)-3-(3-methoxyphenyl)urea
• Synonyms: urea, N-(2-chloroethyl)-N'-(3-methoxyphenyl)-
• CAS NO: 13908-42-4
• Molecular Formula: C₁₀H₁₃ClN₂O₂
• Molecular Weight: 228.6754
• Mol File: 13908-42-4.mol
• Article Data: 4

Chemical Properties

• Boiling Point: 334.9°C at 760 mmHg
• Flash Point: 156.3°C
• Density: 1.248g/cm³
• Vapor Pressure: 0.000124mmHg at 25°C
• Refractive Index: 1.571
• CAS DataBase Reference: 1-(2-chloroethyl)-3-(3-methoxyphenyl)urea(CAS DataBase Reference)
• NIST Chemistry Reference: 1-(2-chloroethyl)-3-(3-methoxyphenyl)urea(13908-42-4)
• EPA Substance Registry System: 1-(2-chloroethyl)-3-(3-methoxyphenyl)urea(13908-42-4)

Safety Data

• Hazardous Substances Data: 13908-42-4(Hazardous Substances Data)

Usage

General Description

1-(2-chloroethyl)-3-(3-methoxyphenyl)urea is a chemical compound with the molecular formula C9H12ClN2O2. It is also known by the trade names Chlorambucil and Leukeran, and is classified as an alkylating agent. 1-(2-chloroethyl)-3-(3-methoxyphenyl)urea exerts its cytotoxic effects by forming covalent bonds with DNA, which inhibits DNA replication and ultimately leads to cell death. Chlorambucil is commonly used in the treatment of various types of cancer, including leukemia and lymphoma. It is a potent chemotherapeutic agent that is typically administered orally or intravenously, and has been shown to be effective in slowing the progress of certain types of cancer and improving overall survival rates. However, it can also cause various side effects, such as bone marrow suppression and an increased risk of infection, and should be used under the supervision of a qualified healthcare professional.

Upstream product

• 1943-83-5 2-chloroethyl isothiocyanate 
• 536-90-3 m-Anisidine 
• 591-27-5 m-Hydroxyaniline 

Downstream Products

• 13909-21-2 C₁₀H₁₂ClN₃O₃ 

Relevant articles and documents

N-Phenyl-N′-(2-chloroethyl)ureas (CEU) as potential antineoplastic agents. Part 2: Role of ω-hydroxyl group in the covalent binding to β-tubulin

Tubulin is the target of many anticancer drugs, including N-phenyl-N′-(2-chloroethyl)urea (CEU). Unlike most anti-β-tubulin agents, CEUs are protein monoalkylating agents binding through their N′-(2-chloroethyl)urea moiety to an amino acid nearby the colchicine-binding site on β-tubulin isoform-2. Following the previously synthesized and attractive N-(3-ω-hydroxyalkylphenyl)-N′-(2-chloroethyl)urea that exhibited growth inhibitory activity at the nanomolar level, we investigated the importance of lower alkyl and alkoxy groups to evaluate the effect of hydroxylated group and chain length on both cell growth inhibition and the mechanism of action of CEU. Here, we describe the preparation of two new series of CEU and show that the most potent CEU derivatives beside the ω-hydroxylated 1f were 2f and 3e, respectively. We have confirmed that the pentyl substituted CEUs 1f, 2f, and 3e are still covalently binding to β-tubulin and still arrest cell division in G2/M phase. Crown Copyright

HALOETHYL UREA COMPOUNDS AND THE USE THEREOF TO ATTENUATE, INHIBIT OR PREVENT CANCER CELL MIGRATION

The present invention provides haloethyl urea compounds as described in Formula (I) and their use as therapeutic agent in the attenuation, inhibition, or prevention of cancer cell migration and cancer cell proliferation.